Gestational Diabetes Mellitus—Recent Literature Review
Open accessThe DOI matches its Crossref record; 122 of the 128 references it cites were found in a registry or an index; 66 of the 129 sources its claims cite were checked for support.
Abstract
GDM is currently the most common medical complication in pregnancy and affects approximately 15% of pregnancies worldwide.
Overview
CoChat Summary
TL;DR
This narrative review summarizes recent literature on gestational diabetes mellitus (GDM), covering epidemiology, pathogenesis, diagnosis, and treatment. It reports that GDM is a common pregnancy complication with rising prevalence and highlights ongoing controversies in diagnostic criteria and treatment, especially regarding metformin and early screening.
Key findings
- GDM is described as the most common medical complication of pregnancy; the abstract reports it affects approximately 15% of pregnancies worldwide and accounts for approximately 18 million births annually, while the introduction cites IDF estimates of approximately 14.0% (95% CI 13.97–14.04%) of pregnancies worldwide, representing approximately 20 million births annually.
- Risk factors include age (GDM diagnosed in 6.7% of pregnancies overall but 8.5% in women over 30; highest risk at ages 35–39, OR 10.85 [7.72–15.25] vs. 2.59 [1.84–3.67]), previous GDM (more than sixfold recurrence risk), BMI ≥30 kg/m² (GDM frequency 12.3%), first-line relatives with GDM history (11.6%), combination of these two factors (up to 61%), PCOS (more than twice the percentage of pregnancies with GDM), IVF (50% increase), and summer season.
- Diagnosis uses IADPSG/WHO criteria (fasting plasma glucose ≥5.1 mmol/L, 1 h ≥10 mmol/L, 2 h ≥8.5 mmol/L during a 75 g OGTT); the HAPO study of 23,316 women showed a linear relationship between elevated glycemia and maternal/neonatal complications, IADPSG criteria produced a threefold increase in GDM diagnoses, and in a trial of 23,792 pregnant women one-step screening doubled GDM diagnosis without affecting LGA, adverse perinatal outcomes, primary Caesarean section, gestational hypertension, or pre-eclampsia.
- Treatment is primarily diet and increased exercise, with insulin, glibenclamide, and metformin used to intensify treatment; the MiG trial of 751 women found metformin alone or with supplemental insulin was not associated with increased perinatal complications, exercise reduced GDM risk by 38% (RR 0.62, 95% CI 0.41–0.94), 24%, and 42% (RR 0.58, 95% CI 0.37–0.90, p = 0.01) in different analyses, and ADA/ACOG still recommend insulin as primary medical treatment when lifestyle goals are not achieved.
Methods
- Narrative literature review analyzing currently available literature on the epidemiology, pathogenesis, diagnosis, and treatment of GDM, based on reviews, original articles, and meta-analyses published in English in the last 10 years.
- Literature search conducted from 1 January 2021 to 31 March 2022 using Web of Science, PubMed, EMBASE, Cochrane, Open Grey, and Grey Literature Report, with MeSH terms including “gestational diabetes”, “pregnancy induced diabetes”, “hyperglycemia”, “glucose intolerance”, “insulin resistance”, “prevalence”, “incidence”, “GDM treatment”, and “behavioral treatment”, used alone or in combination.
- Analysis was a narrative synthesis; no formal systematic review protocol, meta-analysis, or quality appraisal is described.
Limitations
- The paper states that due to the lack of randomized clinical trials, it is extremely difficult to propose an unambiguous and uniform management model; treatment is based on consensus and expert opinion; Cochrane analyses show a lack of unambiguous data on the correlation between intensity of glycemic control and obstetric outcomes; many doubts regarding diagnostic criteria and treatment remain; and screening/treatment for GDM early in pregnancy are very controversial due to lack of data from large randomized controlled trials.
- Evident from the text: this is a narrative review without described systematic quality assessment or PRISMA-style reporting, the search was restricted to English-language publications from the last 10 years, and prevalence figures differ between the abstract (approximately 15%, 18 million births annually) and the introduction (approximately 14.0%, 20 million births annually).
- Evident from the provided text: several subsection headings appear without accompanying content (e.g., 4.4.1 Insulin Resistance and 4.6.1–4.6.3 headings), limiting assessment of those specific details.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
51 Valid · 2 Not valid · 35 Not checked · 8 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The current criteria for the diagnosis of GDM introduced by The International Association of Diabetes and Pregnancy Study Groups (IADPSG), which were based on the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) results, found a threefold increase in GDM diagnoses, which suggests an earlier underestimation.”
§ Gestational Diabetes Mellitus—Recent Literature Review > 4. Results and Discussion > 4.3. Diagnosing GDM
What the sources say
- Partly supportedcites [27] Werner, 2012, Screening for gestational diabetes mellitus: Are the criteria proposed by the International Association of the Diabetes and Pregnancy Study Groups cost-effective?, Diabetes Care sourceExperimental — accuracy not yet measured
The introduction says the IADPSG criteria incorporated HAPO data, and the Conclusions describe a tripling of GDM diagnoses in the U.S. But the Results identify this as a model prediction, not an observed increase: diagnoses would rise from 5,020 to 17,800 per 100,000 women screened. The claim’s wording that the criteria “found” an increase overstates that evidence. Page numbers are unavailable in our copy. (LLM, conf=0.86)
- Not checked — no full text of the sourcecites [28] Williams, 1999, Effect of selective screening for gestational diabetes, Diabetes Care source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The greatest hopes are connected with afamine, adiponectin and 1,5-anhydroglucitol [34,35].”
§ Gestational Diabetes Mellitus—Recent Literature Review > 4. Results and Discussion > 4.3. Diagnosing GDM
What the sources say
- Partly supportedcites [34] Hang, 2019, Predictive and diagnostic biomarkers for gestational diabetes and its associated metabolic and cardiovascular diseases, Cardiovasc. Diabetol. sourceExperimental — accuracy not yet measured
The Conclusion identifies adiponectin, afamin and 1,5-anhydroglucitol as potential predictors of GDM. It also identifies several other candidates and does not rank these three as the most promising. (LLM, conf=0.83)
- Not checked — no full text of the sourcecites [35] Corcoran, 2018, First trimester serum biomarkers to predict gestational diabetes in a high-risk cohort: Striving for clinically useful thresholds, Eur. J. Obstet. Gynecol. Reprod. Biol. source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“GDM in a previous pregnancy increases the risk of reoccurrence by more than six times [17].”
§ Gestational Diabetes Mellitus—Recent Literature Review > 4. Results and Discussion > 4.2. GDM Risk Factors
What the sources say
- Partly supportedcites [17] Kim, 2007, Recurrence of Gestational Diabetes Mellitus A systematic review, Diabetes Care sourceExperimental — accuracy not yet measured
The introduction (p. 1) says women with a history of GDM have an increased risk of recurrent GDM, and Search for published data (p. 2) reports recurrence rates of 30–84% among women who became pregnant again. The paper does not establish that a previous GDM pregnancy increases recurrence risk by more than six times; the reported percentages are recurrence rates, not a sixfold comparison with women without prior GDM. (LLM, conf=0.85)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Screening of only risk groups may result in GDM not being diagnosed in as many as 35–47% of pregnant women, which is certain to affect obstetric results [25].”
§ Gestational Diabetes Mellitus—Recent Literature Review > 4. Results and Discussion > 4.3. Diagnosing GDM
What the sources say
- Partly supportedcites [25] Benhalima, 2013, Analysis of pregnancy outcomes using the new IADPSG recommendation compared with the Carpenter and Coustan criteria in an area with a low prevalence of gestational diabetes, Int. J. Endocrinol. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says a two-step glucose-test strategy may miss some GDM cases, and reports worse pregnancy outcomes among women identified only by the newer diagnostic criteria. It does not assess screening only risk groups or support the claimed 35–47% missed-diagnosis figure; the screening strategy it discusses is different. (LLM, conf=0.85)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“We observe GDM in both obese and lean women [37].”
§ Gestational Diabetes Mellitus—Recent Literature Review > 4. Results and Discussion > 4.4. Pathogenesis of Carbohydrate Metabolism Disorders in Pregnancy
What the sources say
- Supportedcites [37] Yong, 2020, Independent and combined effects of age, body mass index and gestational weight gain on the risk of gestational diabetes mellitus, Sci. Rep. source
Table 2 (Results, ‘Risk factors between non-GDM and GDM women’; page unavailable) reports 131 GDM cases among overweight/obese women and, by subtraction from the 255 total cases, 124 among women outside that group. The Results also compare GDM risk in overweight/obese women with underweight/normal-weight women. The paper uses combined BMI categories rather than reporting separate counts for obese and lean women, but supports the claim that GDM occurs across these weight groups. (LLM, conf=0.86)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
45 more claims · 22 with their cited sources checked
Create a free account to see all 96 claims and to verify the 13 references still open.
- It may state two separate claims as one. 41
- Probably not a substantial claim. 11
- The quote only partly states this claim. 1
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ Gestational Diabetes Mellitus—Recent Literature Review > 1. Introduction
“GDM affects approximately 14.0% (95% confidence interval: 13.97–14.04%) of pregnancies worldwide”
§ Gestational Diabetes Mellitus—Recent Literature Review > 4. Results and Discussion > 4.1. Epidemiology
“more than approximately 20.4 million women (14.0% of pregnancies) presented with disorders of carbohydrate metabolism, of which approximately 80% was GDM”
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Effect of Treatment of Gestational Diabetes Mellitus on Pregnancy Outcomes
Crowther, C. A., Hiller, J. E., Moss, J. R., McPhee, A. J., Jeffries, W. S., & Robinson, J. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042973 · Cited by 3,159
Alogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502
Allotey, J., Fernandez, S., Bonet, M., Stallings, E., Yap, M., Kew, T., Zhou, D., Coomar, D., Sheikh, J., Lawson, H., et al. (2020) · BMJ · doi:10.1136/bmj.m3320 · Cited by 2,304
A Multicenter, Randomized Trial of Treatment for Mild Gestational Diabetes
Landon, M. B., Spong, C. Y., Thom, E., Carpenter, M. W., Ramin, S. M., Casey, B., Wapner, R. J., Varner, M. W., Rouse, D. J., Thorp, J. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902430 · Cited by 2,122 · cited 2×
“Patients who cannot achieve glycemic targets with a properly balanced diet and elimination of dietary errors should be treated pharmacologically [29].”
BackgroundThe Pathophysiology of Gestational Diabetes Mellitus
Plows, J. F., Stanley, J. L., Baker, P. N., Reynolds, C. M., & Vickers, M. H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113342 · Cited by 1,874 · cited 3×
“An increased secretion of insulin-antagonistic hormones (placental hormones, cortisol) during pregnancy results in an increased insulin resistance, which, at the end of the third trimester, reaches a value similar to full-blown type 2 diabetes [9,42].”
BackgroundMcIntyre, H. D., Catalano, P., Zhang, C., Desoye, G., Mathiesen, E. R., & Damm, P. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0098-8 · Cited by 1,850
Metformin versus insulin for the treatment of gestational diabetes
Rowan, J. A., Hague, W. M., Gao, W., Battin, M. R., & Moore, M. P. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707193 · Cited by 1,291
Wang, H., Li, N., Chivese, T., Werfalli, M., Sun, H., Yuen, L., Hoegfeldt, C. A., Elise Powe, C., Immanuel, J., Karuranga, S., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109050 · Cited by 1,260 · cited 5×
“, about one in six births was affected by gestational diabetes [3].”
BackgroundMethodInfluentialCellular Mechanisms for Insulin Resistance in Normal Pregnancy and Gestational Diabetes
Barbour, L. A., McCurdy, C. E., Hernandez, T. L., Kirwan, J. P., Catalano, P. M., & Friedman, J. E. (2007) · Diabetes Care · doi:10.2337/dc07-s202 · Cited by 811
Torloni, M. R., Betrán, A. P., Horta, B. L., Nakamura, M. U., Atallah, A. N., Moron, A. F., & Valente, O. (2009) · Obesity Reviews · doi:10.1111/j.1467-789x.2008.00541.x · Cited by 739 · cited 1×
“The combination of these two factors increases the risk of GDM up to 61% of cases [4,18,19].”
BackgroundTNF-α Is a Predictor of Insulin Resistance in Human Pregnancy
Kirwan, J. P., Hauguel-De Mouzon, S., Lepercq, J., Challier, J.-C., Huston-Presley, L., Friedman, J. E., Kalhan, S. C., & Catalano, P. M. (2002) · Diabetes · doi:10.2337/diabetes.51.7.2207 · Cited by 738 · cited 1×
“stated that an increase in insulin resistance, which is characteristic of pregnancy, most strongly correlates with the increase in TNF-α concentration, considering that TNF-α as a marker of insulin resistance during pregnancy [45].”
BackgroundGestational Diabetes Mellitus: Risks and Management during and after Pregnancy
Buchanan, T. A., Xiang, A. H., & Page, K. A. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.96 · Cited by 718
Lee, K. W., Ching, S. M., Ramachandran, V., Yee, A., Hoo, F. K., Chia, Y. C., Wan Sulaiman, W. A., Suppiah, S., Mohamed, M. H., & Veettil, S. K. (2018) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-018-2131-4 · Cited by 546
Gestational Weight Gain and Pregnancy Outcomes in Obese Women: How Much Is Enough?
Kiel, D. W., Dodson, E. A., Artal, R., Boehmer, T. K., & Leet, T. L. (2007) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000278819.17190.87 · Cited by 498 · cited 1×
“A weight gain of over 18 kg is associated with a twice higher risk of macrosomia [84,85].”
BackgroundCrusell, M. K. W., Hansen, T. H., Nielsen, T., Allin, K. H., Rühlemann, M. C., Damm, P., Vestergaard, H., Rørbye, C., Jørgensen, N. R., Christiansen, O. B., et al. (2018) · Microbiome · doi:10.1186/s40168-018-0472-x · Cited by 480 · cited 1×
“So far, it was shown that in women in the third trimester of pregnancy, GDM was associated with altered intestinal microflora [87].”
BackgroundRole of the Gut Microbiome in the Pathogenesis of Obesity and Obesity-Related Metabolic Dysfunction
Bouter, K. E., van Raalte, D. H., Groen, A. K., & Nieuwdorp, M. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.12.048 · Cited by 431
Buchanan, T. A., Xiang, A., Kjos, S. L., & Watanabe, R. (2007) · Diabetes Care · doi:10.2337/dc07-s201 · Cited by 417
Estimated global overweight and obesity burden in pregnant women based on panel data model
Chen, C., Xu, X., & Yan, Y. (2018) · PLOS ONE · doi:10.1371/journal.pone.0202183 · Cited by 415 · cited 1×
“The growing problem of overweight and obesity around the world significantly contributes to the steady increase in the incidence of diabetes, including GDM in the population of women of reproductive age [11].”
BackgroundHAPO Study Cooperative Research Group (2010) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.2009.02486.x · Cited by 395
14. Management of Diabetes in Pregnancy:Standards of Medical Care in Diabetes—2020
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s014 · Cited by 381
Recurrence of Gestational Diabetes Mellitus
Kim, C., Berger, D. K., & Chamany, S. (2007) · Diabetes Care · doi:10.2337/dc06-2517 · Cited by 367
Buckley, B. S., Harreiter, J., Damm, P., Corcoy, R., Chico, A., Simmons, D., Vellinga, A., Dunne, F., & on behalf of the DALI Core Investigator Group (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03541.x · Cited by 360
Horvath, K., Koch, K., Jeitler, K., Matyas, E., Bender, R., Bastian, H., Lange, S., & Siebenhofer, A. (2010) · BMJ · doi:10.1136/bmj.c1395 · Cited by 359
Sun, Y., Shen, Z., Zhan, Y., Wang, Y., Ma, S., Zhang, S., Liu, J., Wu, S., Feng, Y., Chen, Y., et al. (2020) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-020-03071-y · Cited by 319
Rowan, J. A., Rush, E. C., Plank, L. D., Lu, J., Obolonkin, V., Coat, S., & Hague, W. M. (2018) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2017-000456 · Cited by 305
Diet and Healthy Lifestyle in the Management of Gestational Diabetes Mellitus
Rasmussen, L., Poulsen, C. W., Kampmann, U., Smedegaard, S. B., Ovesen, P. G., & Fuglsang, J. (2020) · Nutrients · doi:10.3390/nu12103050 · Cited by 304
A pragmatic, randomized clinical trial of gestational diabetes screening
Hillier, T. A., Pedula, K. L., Ogasawara, K. K., Vesco, K. K., Oshiro, C. E. S., Lubarsky, S. L., & Van Marter, J. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2026028 · Cited by 270
Baz, B., Riveline, J.-P., & Gautier, J.-F. (2016) · European Journal of Endocrinology · doi:10.1530/eje-15-0378 · Cited by 260
Leptin, adiponectin and other adipokines in gestational diabetes mellitus and pre‐eclampsia
Miehle, K., Stepan, H., & Fasshauer, M. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2011.04234.x · Cited by 236
Schwartz, N., Nachum, Z., & Green, M. S. (2015) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2015.03.011 · Cited by 229 · cited 1×
“Even after taking into account the age of the woman, pluriparity remains in a linear relationship to the incidence of GDM [16].”
BackgroundPlacental-fetal glucose exchange and fetal glucose metabolism.
(2006) · Europe PMC (PubMed Central) · Cited by 226
Insulin Secretion during and after Pregnancy in Patients with Gestational Diabetes Mellitus1
Homko, C., Sivan, E., Chen, X., Reece, E. A., & Boden, G. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.2.7137 · Cited by 217
β-cell adaptation in pregnancy
Baeyens, L., Hindi, S., Sorenson, R. L., & German, M. S. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12716 · Cited by 210
Obstetric outcome in women with polycystic ovarian syndrome
Mikola, M. (2001) · Human Reproduction · doi:10.1093/humrep/16.2.226 · Cited by 206 · cited 1×
“More than twice the percentage of pregnancies with GDM was observed in women that were previously treated for polycystic ovary syndrome (PCOS) [20].”
BackgroundLorenzo-Almorós, A., Hang, T., Peiró, C., Soriano-Guillén, L., Egido, J., Tuñón, J., & Lorenzo, Ó. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0935-9 · Cited by 202 · cited 1×
“The greatest hopes are connected with afamine, adiponectin and 1,5 -anhydroglucitol [34,35].”
BackgroundCallaway, L. K., McIntyre, H. D., Barrett, H. L., Foxcroft, K., Tremellen, A., Lingwood, B. E., Tobin, J. M., Wilkinson, S., Kothari, A., Morrison, M., et al. (2019) · Diabetes Care · doi:10.2337/dc18-2248 · Cited by 187
Werner, E. F., Pettker, C. M., Zuckerwise, L., Reel, M., Funai, E. F., Henderson, J., & Thung, S. F. (2012) · Diabetes Care · doi:10.2337/dc11-1643 · Cited by 182 · cited 1×
“Moreover, the study authors found that perinatal risks began to increase in women with glucose values that were previously considered “normal” [27,28].”
BackgroundEberle, C., & Stichling, S. (2021) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-021-00705-9 · Cited by 181 · cited 2×
“Their presence is associated with an impaired first phase of insulin secretion in DM2 and GDM and leads to a decrease in the mass of beta cells and impairment of their function, leading to GDM [53,54].”
BackgroundHod, M., Damm, P., Kaaja, R., Visser, G. H. A., Dunne, F., Demidova, I., Hansen, A.-S. P., & Mersebach, H. (2008) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2007.08.005 · Cited by 176
Kijmanawat, A., Panburana, P., Reutrakul, S., & Tangshewinsirikul, C. (2019) · Journal of Diabetes Investigation · doi:10.1111/jdi.12863 · Cited by 174
Aune, D., Sen, A., Henriksen, T., Saugstad, O. D., & Tonstad, S. (2016) · European Journal of Epidemiology · doi:10.1007/s10654-016-0176-0 · Cited by 170
Insulin for the treatment of women with gestational diabetes
Brown, J., Grzeskowiak, L., Williamson, K., Downie, M. R., & Crowther, C. A. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012037.pub2 · Cited by 158
Insulin Secretion during and after Pregnancy in Patients with Gestational Diabetes Mellitus
Cj, H. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.2.568 · Cited by 156
Increased Maternal Plasma Leptin in Early Pregnancy and Risk of Gestational Diabetes Mellitus
Qiu, C., Williams, M. A., Vadachkoria, S., Frederick, I. O., & Luthy, D. A. (2004) · Obstetrics & Gynecology · doi:10.1097/01.aog.0000113621.53602.7a · Cited by 146 · cited 1×
“For every 10 ng/mL increase in leptin concentration, the risk of GDM increases by 21% [46].”
BackgroundPellonperä, O., Mokkala, K., Houttu, N., Vahlberg, T., Koivuniemi, E., Tertti, K., Rönnemaa, T., & Laitinen, K. (2019) · Diabetes Care · doi:10.2337/dc18-2591 · Cited by 145
Increased global placental DNA methylation levels are associated with gestational diabetes
Reichetzeder, C., Dwi Putra, S. E., Pfab, T., Slowinski, T., Neuber, C., Kleuser, B., & Hocher, B. (2016) · Clinical Epigenetics · doi:10.1186/s13148-016-0247-9 · Cited by 144
Hernandez, T. L., Van Pelt, R. E., Anderson, M. A., Daniels, L. J., West, N. A., Donahoo, W. T., Friedman, J. E., & Barbour, L. A. (2014) · Diabetes Care · doi:10.2337/dc13-2411 · Cited by 141
Maternal Age and Prevalence of Gestational Diabetes Mellitus
Lao, T. T., Ho, L.-F., Chan, B. C. P., & Leung, W.-C. (2006) · Diabetes Care · doi:10.2337/diacare.29.04.06.dc05-2568 · Cited by 138
Mao, H., Li, Q., & Gao, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0045882 · Cited by 132 · cited 1×
“with an impaired first phase of insulin secretion in DM2 and GDM and leads to a decrease in the mass of beta cells and impairment of their function, leading to GDM [53,54].”
BackgroundPathophysiology of Gestational Diabetes Mellitus
Berberoglu, Z. (2019) · EMJ Diabetes · doi:10.33590/emjdiabet/10313616 · Cited by 129
Lower versus Higher Glycemic Criteria for Diagnosis of Gestational Diabetes
Crowther, C. A., Samuel, D., McCowan, L. M. E., Edlin, R., Tran, T., & McKinlay, C. J. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204091 · Cited by 120 · cited 1×
“The recently published results of the GEMS Trial showed that lower glycemic criteria (fasting plasma glucose level of at least 92 mg/dL, a 1 h level of at least 180 mg/dL or a 2 h level of at least 153 mg/dL) for the diagnosis of GDM did not result in a lower risk of a large-for-gestational-age infant than the use of…”
BackgroundAsemi, Z., Samimi, M., Tabassi, Z., & Esmaillzadeh, A. (2014) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2013.296 · Cited by 119
Vrachnis, N., Belitsos, P., Sifakis, S., Dafopoulos, K., Siristatidis, C., Pappa, K. I., & Iliodromiti, Z. (2012) · International Journal of Endocrinology · doi:10.1155/2012/549748 · Cited by 119
Allotey, J., Stallings, E., Bonet, M., Yap, M. M. P., Chatterjee, S., Kew, T., Debenham, L. J., Llavall, A. C., Dixit, A., Zhou, D., et al. (2021) · Obstetric Anesthesia Digest · doi:10.1097/01.aoa.0000744128.44930.48 · Cited by 119
Xu, T., Dainelli, L., Yu, K., Ma, L., Silva Zolezzi, I., Detzel, P., & Fang, H. (2017) · BMJ Open · doi:10.1136/bmjopen-2017-018893 · Cited by 116
Ming, W.-K., Ding, W., Zhang, C. J. P., Zhong, L., Long, Y., Li, Z., Sun, C., Wu, Y., Chen, H., Chen, H., et al. (2018) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-018-2068-7 · Cited by 114
Yong, H. Y., Mohd Shariff, Z., Mohd Yusof, B. N., Rejali, Z., Tee, Y. Y. S., Bindels, J., & van der Beek, E. M. (2020) · Scientific Reports · doi:10.1038/s41598-020-65251-2 · Cited by 113
Diet in pregnancy—more than food
Danielewicz, H., Myszczyszyn, G., Dębińska, A., Myszkal, A., Boznański, A., & Hirnle, L. (2017) · European Journal of Pediatrics · doi:10.1007/s00431-017-3026-5 · Cited by 111
Genetics of Gestational Diabetes Mellitus and Maternal Metabolism
Lowe, W. L., Scholtens, D. M., Sandler, V., & Hayes, M. G. (2016) · Current Diabetes Reports · doi:10.1007/s11892-015-0709-z · Cited by 108 · cited 1×
“with an impaired first phase of insulin secretion in DM2 and GDM and leads to a decrease in the mass of beta cells and impairment of their function, leading to GDM [53,54].”
BackgroundHod, M., Mathiesen, E. R., Jovanovič, L., McCance, D. R., Ivanisevic, M., Durán-Garcia, S., Brøndsted, L., Nazeri, A., & Damm, P. (2014) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.3109/14767058.2013.799650 · Cited by 100
Exercise for pregnant women with gestational diabetes for improving maternal and fetal outcomes
Brown, J., Ceysens, G., & Boulvain, M. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012202.pub2 · Cited by 98
Harrison, A. L., Shields, N., Taylor, N. F., & Frawley, H. C. (2016) · Journal of Physiotherapy · doi:10.1016/j.jphys.2016.08.003 · Cited by 97
COVID-19 pandemic: Impact on gestational diabetes mellitus prevalence
Zanardo, V., Tortora, D., Sandri, A., Severino, L., Mesirca, P., & Straface, G. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109149 · Cited by 93
McIntyre, H. D., Gibbons, K. S., Ma, R. C. W., Tam, W. H., Sacks, D. A., Lowe, J., Madsen, L. R., & Catalano, P. M. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108353 · Cited by 81
The use of glyburide in the management of gestational diabetes mellitus: A meta-analysis
Zeng, Y.-C., Li, M.-J., Chen, Y., Jiang, L., Wang, S.-M., Mo, X.-L., & Li, B.-Y. (2014) · Advances in Medical Sciences · doi:10.1016/j.advms.2014.03.001 · Cited by 76
Benhalima, K., Hanssens, M., Devlieger, R., Verhaeghe, J., & Mathieu, C. (2013) · International Journal of Endocrinology · doi:10.1155/2013/248121 · Cited by 73 · cited 1×
“Screening of only risk groups may result in GDM not being diagnosed in as many as 35–47% of pregnant women, which is certain to affect obstetric results [25].”
BackgroundSchneeberger, C., Kazemier, B. M., & Geerlings, S. E. (2014) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000028 · Cited by 73
The treatment of booking gestational diabetes mellitus (TOBOGM) pilot randomised controlled trial
Simmons, D., Nema, J., Parton, C., Vizza, L., Robertson, A., Rajagopal, R., Ussher, J., & Perz, J. (2018) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-018-1809-y · Cited by 71
Effects of COVID-19 pandemic lockdown on gestational diabetes mellitus: A retrospective study
Ghesquière, L., Garabedian, C., Drumez, E., Lemaître, M., Cazaubiel, M., Bengler, C., & Vambergue, A. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.09.008 · Cited by 71 · cited 2×
“Their presence is associated with an impaired first phase of insulin secretion in DM2 and GDM and leads to a decrease in the mass of beta cells and impairment of their function, leading to GDM [53,54].”
BackgroundNasiri-Amiri, F., Sepidarkish, M., Shirvani, M. A., Habibipour, P., & Tabari, N. S. M. (2019) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-019-0470-6 · Cited by 67
Metformin from mother to unborn child-are there unwarranted effects?
Nguyen, L., Chan, S.-Y., & Teo, A. K. K. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.08.047 · Cited by 67
Insulin Use in Pregnancy: An Update
Blum, A. K. (2016) · Diabetes Spectrum · doi:10.2337/diaspect.29.2.92 · Cited by 59
McIntyre, H. D., & Moses, R. G. (2020) · Diabetes Care · doi:10.2337/dci20-0026 · Cited by 58
Effect of selective screening for gestational diabetes.
Williams, C. B., Iqbal, S., Zawacki, C. M., Yu, D., Brown, M. B., & Herman, W. H. (1999) · Diabetes Care · doi:10.2337/diacare.22.3.418 · Cited by 57
Lenoir-Wijnkoop, I., van der Beek, E. M., Garssen, J., Nuijten, M. J. C., & Uauy, R. D. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00103 · Cited by 57
Yu, D., Xu, G., Teng, X., Xu, J., Tang, L., Feng, C., Rao, J., Jin, M., & Wang, L. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-021-00865-9 · Cited by 56
Insulin for the treatment of women with gestational diabetes
Brown, J., Grzeskowiak, L. E., Williamson, K. A., Downie, M. R., & Crowther, C. A. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012037 · Cited by 52
The Effect of Soy Intake on Metabolic Profiles of Women With Gestational Diabetes Mellitus
Jamilian, M., & Asemi, Z. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-3454 · Cited by 49
Hillyard, M., Sinclair, M., Murphy, M., Casson, K., & Mulligan, C. (2021) · PLOS ONE · doi:10.1371/journal.pone.0254364 · Cited by 49
Brown, J., Crawford, T. J., Alsweiler, J., & Crowther, C. A. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012048.pub2 · Cited by 48
Gjesing, A. P., Rui, G., Lauenborg, J., Have, C. T., Hollensted, M., Andersson, E., Grarup, N., Sun, J., Quan, S., Brandslund, I., et al. (2017) · Journal of the Endocrine Society · doi:10.1210/js.2017-00040 · Cited by 43 · cited 1×
“In cross-sectional studies, the prevalence of mutations in the gene variants GCK, HNF1A, HNF4A, HNF1B and INS in maturity-onset diabetes of the young (MODY) was 0–5% [52].”
BackgroundDifferent intensities of glycaemic control for women with gestational diabetes mellitus
Martis, R., Brown, J., Alsweiler, J., Crawford, T. J., & Crowther, C. A. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011624.pub2 · Cited by 41
Ott, R., Melchior, K., Stupin, J. H., Ziska, T., Schellong, K., Henrich, W., Rancourt, R. C., & Plagemann, A. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01659 · Cited by 41
Seasonal Pattern in the Diagnosis of Gestational Diabetes Mellitus in Southern Sweden
Katsarou, A., Claesson, R., Ignell, C., Shaat, N., & Berntorp, K. (2016) · Journal of Diabetes Research · doi:10.1155/2016/8905474 · Cited by 41
Maple-Brown, L., Ye, C., Hanley, A. J., Connelly, P. W., Sermer, M., Zinman, B., & Retnakaran, R. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-2290 · Cited by 41 · cited 1×
“However, pre-pregnancy BMI is a stronger predictor of leptinemia than GDM perse [48].”
BackgroundCorcoran, S. M., Achamallah, N., Loughlin, J. O., Stafford, P., Dicker, P., Malone, F. D., & Breathnach, F. (2018) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2017.12.051 · Cited by 40 · cited 1×
“The greatest hopes are connected with afamine, adiponectin and 1,5 -anhydroglucitol [34,35].”
Backgroundvan Gemert, T. E., Moses, R. G., Pape, A. V., & Morris, G. J. (2020) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/ajo.13203 · Cited by 40
Lee, H., Wei, D., & Loeken, M. R. (2014) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2451 · Cited by 39
New Insights into Adipokines in Gestational Diabetes Mellitus
Valencia-Ortega, J., González-Reynoso, R., Ramos-Martínez, E. G., Ferreira-Hermosillo, A., Peña-Cano, M. I., Morales-Ávila, E., & Saucedo, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23116279 · Cited by 39 · cited 1×
“It was shown that a low adiponectin concentration in the first and second trimesters of pregnancy is a predictor of diabetes development in pregnancy [50].”
BackgroundImpact of Seasonality on Gestational Diabetes Mellitus
Chiefari, E., Pastore, I., Puccio, L., Caroleo, P., Oliverio, R., Vero, A., Foti, D. P., Vero, R., & Brunetti, A. (2017) · Endocrine, Metabolic & Immune Disorders - Drug Targets · doi:10.2174/1871530317666170808155526 · Cited by 38
Mitanchez, D., Ciangura, C., & Jacqueminet, S. (2020) · Nutrients · doi:10.3390/nu12020353 · Cited by 37 · cited 1×
“indicated that the greatest impact on reducing the number of obstetric complications is achieved by combining dietary treatment with exercise [72].”
BackgroundPan, J., Pan, Q., Chen, Y., Zhang, H., & Zheng, X. (2019) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2017.1376318 · Cited by 35
Kondracki, A. J., Valente, M. J., Ibrahimou, B., & Bursac, Z. (2022) · Paediatric and Perinatal Epidemiology · doi:10.1111/ppe.12809 · Cited by 34 · cited 2×
“The combination of these two factors increases the risk of GDM up to 61% of cases [4,18,19].”
BackgroundNouhjah, S., Jahanfar, S., & Shahbazian, H. B. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.06.030 · Cited by 33
Assi, E., D'Addio, F., Mandò, C., Maestroni, A., Loretelli, C., Ben Nasr, M., Usuelli, V., Abdelsalam, A., Seelam, A. J., Pastore, I., et al. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001586 · Cited by 30
Morris, M. A., Hutchinson, J., Gianfrancesco, C., Alwan, N. A., Carter, M. C., Scott, E. M., & Cade, J. E. (2019) · Nutrients · doi:10.3390/nu12010003 · Cited by 30
Exercise for pregnant women with pre-existing diabetes for improving maternal and fetal outcomes
Brown, J., Ceysens, G., & Boulvain, M. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012696.pub2 · Cited by 30
Elshani, B. D., Kotori, V. M., & Daci, A. (2019) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2019.1593361 · Cited by 29
Song, X., Chen, L., Zhang, S., Liu, Y., Wei, J., Wang, T., & Qin, J. (2022) · Nutrients · doi:10.3390/nu14163347 · Cited by 28
Performance of early risk assessment tools to predict the later development of gestational diabetes
Kotzaeridi, G., Blätter, J., Eppel, D., Rosicky, I., Mittlböck, M., Yerlikaya‐Schatten, G., Schatten, C., Husslein, P., Eppel, W., Huhn, E. A., et al. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13630 · Cited by 27 · cited 1×
“The Benhalim-2 2020 model, which takes into account interview and biochemical data (propensity score model: history of GDM, FPG, height, triglycerides, age, ethnic origin, first trimester weight, family history of diabetes, HbA1c), showed the highest sensitivity [36].”
MethodGestational diabetes: Do all women need to be tested?
Moses, R., Griffiths, R., & Davis, W. (1995) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/j.1479-828x.1995.tb02148.x · Cited by 27
Nørgaard, K., Sukumar, N., Rafnsson, S. B., & Saravanan, P. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0411-7 · Cited by 26
Zhang, Y., Chen, Y., Qu, H., & Wang, Y. (2019) · Molecular Genetics & Genomic Medicine · doi:10.1002/mgg3.583 · Cited by 22
Oliveira, M. M. D., Andrade, K. F. D. O., Lima, G. H. S., & Rocha, T. C. (2022) · Einstein (São Paulo) · doi:10.31744/einstein_journal/2022rw6155 · Cited by 21 · cited 1×
“In developing countries, such as Brazil, oral hypoglycemic agents are also used, mainly metformin and glibenclamide (glyburide) [10].”
BackgroundThe risk of diabetes after giving birth to a macrosomic infant: data from the NHANES cohort
Miller, C., & Lim, E. (2021) · Maternal Health, Neonatology and Perinatology · doi:10.1186/s40748-021-00132-8 · Cited by 21
de Oliveira, M. M., Andrade, K. F. D. O., Lima, G. H. S., & Rocha, T. C. (2022) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) · Cited by 19
Barabash, A., Valerio, J. D., Garcia de la Torre, N., Jimenez, I., del Valle, L., Melero, V., Assaf-Balut, C., Fuentes, M., Bordiu, E., Durán, A., et al. (2020) · Metabolism Open · doi:10.1016/j.metop.2020.100069 · Cited by 18
Chen, C., Huang, Y., Dong, G., Zeng, Y., & Zhou, Z. (2020) · Gynecological Endocrinology · doi:10.1080/09513590.2019.1703943 · Cited by 18
ACOG Committee Opinion, Number 247, December 2000
(2003) · doi:10.1016/s0020-7292(03)00278-9 · Cited by 17
Aubry, E. M., Raio, L., & Oelhafen, S. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108830 · Cited by 17 · cited 1×
“The introduction of the IADPSG criteria for the screening of GDM increased the prevalence by threefold, albeit with no substantial improvements in GDM-related events for women without risk factors except for reduced risks for LGA, neonatal hypoglycemia and preterm birth [31].”
Options for screening for gestational diabetes mellitus during the SARS‐CoV‐2 pandemic
Simmons, D., Rudland, V. L., Wong, V., Flack, J., Mackie, A., Ross, G. P., Coat, S., Dalal, R., Hague, B. M., & Cheung, N. W. (2020) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/ajo.13224 · Cited by 16
Crawford, T. J., Crowther, C. A., Alsweiler, J. M., & Brown, J. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012048 · Cited by 15
Non-pharmacological management of gestational diabetes: The role of myo-inositol
Guardo, F. D., Currò, J. M., Valenti, G., Rossetti, P., Di Gregorio, L. M., Conway, F., Chiofalo, B., Garzon, S., Bruni, S., & Rizzo, G. (2020) · Journal of Complementary and Integrative Medicine · doi:10.1515/jcim-2019-0111 · Cited by 14 · cited 1×
“Myoinositol (vitamin B8) supplementation or a diet rich in the MYO-INS isomer may improve glycemic control in GDM [94,95].”
BackgroundSarathi, V., Kolly, A., Chaithanya, H. B., & Dwarakanath, C. S. (2016) · Romanian Journal of Diabetes Nutrition and Metabolic Diseases · doi:10.1515/rjdnmd-2016-0024 · Cited by 14 · cited 1×
“indicated that eating a high-protein diet based on soy products reduces insulin requirements in GDM patients [92,93].”
BackgroundInsulin Glargine Use During Pregnancy
Pantalone, K. M., Faiman, C., & Olansky, L. (2011) · Endocrine Practice · doi:10.4158/ep11083.ra · Cited by 13
Honnorat, D., Disse, E., Millot, L., Mathiotte, E., Claret, M., Charrie, A., Drai, J., Garnier, L., Maurice, C., Durand, E., et al. (2015) · Diabetes & Metabolism · doi:10.1016/j.diabet.2015.03.003 · Cited by 12
Mathiesen, E. R., Andersen, H., Kring, S. I. I., & Damm, P. (2017) · BMC Pregnancy and Childbirth · doi:10.1186/s12884-016-1177-4 · Cited by 12
Tumor necrosis factor- α, adiponectin and their ratio in gestational diabetes mellitus.
(2018) · Europe PMC (PubMed Central) · doi:10.22088/cjim.9.1.71 · Cited by 10 · cited 1×
“The ratio of adiponectin/TNF-α, which decrease significantly in GDM compared with normal pregnancy, might be an informative biomarker for the assessment of pregnant women at high risk of insulin resistance and dyslipidemia and for the diagnosis and therapeutic monitoring aims regarding GDM [60].”
BackgroundSeasonality of gestational diabetes mellitus and maternal blood glucose levels: Evidence from Taiwan
Wang, P., Wu, C.-S., Li, C.-Y., Yang, C.-P., & Lu, M.-C. (2020) · Medicine · doi:10.1097/md.0000000000022684 · Cited by 10
Advances in Oral Anti‐Diabetes Drugs in Pregnancy
Mukerji, G., & Feig, D. S. (2017) · A Practical Manual of Diabetes in Pregnancy · doi:10.1002/9781119043805.ch15 · Cited by 2
1392-P: Assisted Reproduction Technology Treatment and Risk of Gestational Diabetes
BIANCHI, C., PELLE, C. D., GENNARO, G. D., ARAGONA, M., CELA, V., DELPRATO, S., & BERTOLOTTO, A. (2020) · Diabetes · doi:10.2337/db20-1392-p · Cited by 1
Research works printed but not linked: 3
- Kumar, 2020, Autoimmunity in Gestational Diabetes A Decade after the HAPO Study, Front. Diabetes, 28, 234
- Chao, 2019, Dietary control plus nutrition guidance for blood glucose and pregnancy outcomes in women with gestational diabetes, Int. J. Clin. Exp. Med., 12, 2773
- Rasmussen, K.M., and Yaktine, A.L. (2009). Weight Gain During Pregnancy: Reexamining the Guidelines (2009), The National Academies Press.
Cited by
Reproductive risk factors across the female lifecourse and later metabolic health
Nichols, A. R., Chavarro, J. E., & Oken, E. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.01.002 · Cited by 76
Polystyrene microplastics disturb maternal glucose homeostasis and induce adverse pregnancy outcomes
Zhang, R., Feng, Y., Nie, P., Wang, W., Wu, H., Wan, X., Xu, H., & Fu, F. (2024) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2024.116492 · Cited by 46
Gao, Y., Hu, Y., & Xiang, L. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04322-0 · Cited by 37
Xie, W., Zhang, L., Cheng, J., Wang, Y., Kang, H., & Gao, Y. (2024) · BMC Public Health · doi:10.1186/s12889-024-18131-7 · Cited by 41
“…of both the mother and infant is adversely affected by GDM: pregnant women with GDM have a greater risk of obesity and hypertension in the short term, while the long-term risks for offspring born to mothers with GDM include an increased risk of developing type 2 diabetes mellitus (T2DM) [5, 6].”
BackgroundThyroid dysfunction during gestation and gestational diabetes mellitus: a complex relationship
Pinto, S., Croce, L., Lea, C., Cosson, E., & Rotondi, M. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02079-3 · Cited by 44
Metadata
- Authors
- Modzelewski, R., Stefanowicz-Rutkowska, M. M., Matuszewski, W., & Bandurska-Stankiewicz, E. M.
- Affiliations
- University of Warmia and Mazury in Olsztyn (PL)
- Wroclaw Medical University (PL)
- Corresponding author
- Stefanowicz-Rutkowska, Magdalena Maria
- ORCID
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2022-09-28
- Volume
- 11
- Issue
- 19
- Pages
- 5736
- ISSN
- 2077-0383 (ISSN-L)
- PMC
- PMC9572242
- OpenAlex
- W4297478345
- Cited by
- 223
- References
- 128
- Citations by year
- 2026: 65 · 2025: 74 · 2024: 62 · 2023: 22
- FWCI
- 7.94
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- gestational diabetes mellitus, hyperglycemia in pregnancy, risk factors, pathogenesis, SARS-CoV-2, diagnosis, treatment, insulin, metformin, glibenclamide, diet and exercise, type 2 diabetes risk, perinatal complications, economic burden
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.